Frequently Asked
Questions

Yes. CrisprPharmaceuticals.com is owned and actively offered for direct sale through this listing. There are no intermediary brokers, active competing bids, or auction processes in progress. The domain is available for immediate private negotiation with qualified buyers.

Pricing is disclosed directly to qualified inquirers, not publicly posted. This allows for a proper conversation about fit, intended use, and timeline. Serious buyers will receive full pricing details within 24 hours of submitting an inquiry. If your organization requires an NDA before pricing is shared, that can be accommodated.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a scientific descriptive term, not a proprietary brand name that can be exclusively owned. However, CRISPR Therapeutics AG is a specific company name with its own trademark registrations for their entity. We strongly recommend consulting with a qualified IP attorney before using "CRISPR" in your company name or trademark registration. The domain name itself — as a descriptive address — is separate from trademark considerations and is available for purchase. Your attorney can advise on the appropriate path to trademark clearance for your intended use.

Once price and terms are agreed, we use an industry-standard escrow service — Escrow.com or Sedo Escrow — to protect both parties. The buyer deposits funds into escrow; the domain is transferred to the buyer's designated registrar account; the buyer confirms receipt; funds are released to the seller. The entire process typically takes 5–10 business days. For buyers at the same registrar, push transfers can be completed much faster.

Installment arrangements can be considered for well-funded or institutional buyers. Typically this involves a meaningful upfront payment with the balance due within 6–12 months under a signed asset purchase agreement. The domain is held in escrow or under a lease-to-own structure until the final payment is received. Please specify your preferred payment structure in your initial inquiry.

No. This listing is operated by the private owner of the domain CrisprPharmaceuticals.com. It has no affiliation with CRISPR Therapeutics AG (CRSP), Editas Medicine, Beam Therapeutics, Intellia Therapeutics, Prime Medicine, or any other named entity in the gene editing space. References to these companies on this site are purely for market context and valuation comparison purposes.

The core sale is for the domain name CrisprPharmaceuticals.com. This listing website is included as a courtesy deliverable. If social handles associated with the name have been registered (e.g., on X/Twitter, LinkedIn, or Instagram), their potential inclusion or separate transfer can be discussed during negotiations. All specifics are negotiable.

Absolutely. We can provide a draft Asset Purchase Agreement for your legal team's review prior to any binding commitment. For enterprise buyers with internal procurement or legal review requirements, we're experienced in accommodating vendor onboarding processes, legal hold periods, and multi-party sign-off workflows. We can also work from your organization's preferred agreement template if you have one.

With escrow, the full transfer process typically completes in 5–10 business days. If timing is critical — for instance, ahead of a funding announcement, product launch, or conference presentation — please indicate your deadline in your inquiry and we will do everything possible to accommodate an expedited timeline. Same-registrar transfers can often be completed within 24–48 hours once funds are in escrow.